AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Recent advancements in the treatment of ATTR cardiomyopathy have significantly changed management strategies. The approval of tafamidis in 2019 marked a turning point, offering patients a substantial treatment effect, especially when diagnosed early. Following this, acaramidis has emerged as a promising agent that stabilizes transthyretin proteins, reducing cardiovascular hospitalizations by approximately 50%. These therapies, alongside newer developments, exemplify the progress made in addressing a previously challenging and often overlooked condition.